Suppr超能文献

心肌活检对射血分数保留心力衰竭的特征分析及心脏淀粉样变性的患病率。

Endomyocardial Biopsy Characterization of Heart Failure With Preserved Ejection Fraction and Prevalence of Cardiac Amyloidosis.

机构信息

Division of Cardiology, The Johns Hopkins School of Medicine, Baltimore, Maryland.

Division of General Internal Medicine, The Johns Hopkins School of Medicine, Baltimore, Maryland.

出版信息

JACC Heart Fail. 2020 Sep;8(9):712-724. doi: 10.1016/j.jchf.2020.04.007. Epub 2020 Jul 8.

Abstract

OBJECTIVES

This study prospectively evaluated endomyocardial biopsies in patients with heart failure with preserved ejection fraction (HFpEF) to identify histopathologic phenotypes and their association with clinical characteristics.

BACKGROUND

Myocardial tissue analysis from a prospectively defined HFpEF cohort reflecting contemporary comorbidities is lacking.

METHODS

Patients with HFpEF (EF ≥50%) referred to the Johns Hopkins HFpEF Clinic between August 2014 and September 2018 were enrolled for right heart catheterization and endomyocardial biopsy. Clinical features, echocardiography, hemodynamics, and tissue histology were determined and compared with controls (unused donor hearts) and HF with reduced EF (HFrEF).

RESULTS

Of the 108 patients enrolled, median age was 66 years (25th to 75th percentile: 57 to 74 years), 61% were women, 57% were African American, 62% had a previous HF hospitalization, median systolic blood pressure was 141 mm Hg (25th to 75th percentile: 125 to 162 mm Hg), body mass index (BMI) was 37 kg/m (25th to 75th percentile: 32 to 45 kg/m), and 97% were on a loop diuretic. Myocardial fibrosis and myocyte hypertrophy were often present (93% and 88%, respectively); however, mild in 71% with fibrosis and in 52% with hypertrophy. Monocyte infiltration (CD68+ cells/mm) was greater in patients with HFpEF versus controls (60.4 cells/mm [25th to 75th percentile: 36.8 to 97.8] vs. 32.1 cells/mm [25th to 75th percentile: 22.3 to 59.2]; p = 0.02) and correlated with age and renal disease. Cardiac amyloidosis (CA) was diagnosed in 15 (14%) patients (HFpEF-CA: 7 patients with wild-type transthyretin amyloidosis [ATTR], 4 patients with hereditary ATTR, 3 patients with light-chain amyloidosis, and 1 patient with AA (secondary) amyloidosis), of which 7 cases were unsuspected. Patients with HFpEF-CA were older, with lower BMI, higher left ventricular mass index, and higher N-terminal pro-B-type natriuretic peptide and troponin I levels.

CONCLUSIONS

In this large, prospective myocardial tissue analysis of HFpEF, myocardial fibrosis and hypertrophy were common, CD68+ inflammation was increased, and CA prevalence was 14%. Tissue analysis in HFpEF might improve precision therapies by identifying relevant myocardial mechanisms.

摘要

目的

本研究前瞻性评估射血分数保留型心力衰竭(HFpEF)患者的心内膜心肌活检,以确定组织病理学表型及其与临床特征的关系。

背景

缺乏反映当代合并症的前瞻性定义的 HFpEF 队列的心肌组织分析。

方法

2014 年 8 月至 2018 年 9 月期间,因 HFpEF 被转诊至约翰霍普金斯 HFpEF 诊所的患者接受右心导管检查和心内膜心肌活检。确定临床特征、超声心动图、血液动力学和组织病理学,并与对照组(未使用的供体心脏)和射血分数降低的心力衰竭(HFrEF)进行比较。

结果

在纳入的 108 例患者中,中位年龄为 66 岁(25%至 75%分位:57 至 74 岁),61%为女性,57%为非裔美国人,62%有 HF 住院史,中位收缩压为 141mmHg(25%至 75%分位:125 至 162mmHg),体重指数(BMI)为 37kg/m(25%至 75%分位:32 至 45kg/m),97%服用袢利尿剂。心肌纤维化和心肌细胞肥大常存在(分别为 93%和 88%);然而,纤维化中有 71%和肥大中有 52%为轻度。与对照组相比,HFpEF 患者的单核细胞浸润(CD68+细胞/mm)更高(60.4 个细胞/mm[25%至 75%分位:36.8 至 97.8]比 32.1 个细胞/mm[25%至 75%分位:22.3 至 59.2];p=0.02),并与年龄和肾脏疾病相关。15 例(14%)患者诊断为心脏淀粉样变性(CA)(HFpEF-CA:7 例野生型转甲状腺素蛋白淀粉样变性[ATTR],4 例遗传性ATTR,3 例轻链淀粉样变性,1 例 AA(继发性)淀粉样变性),其中 7 例为意外发现。HFpEF-CA 患者年龄较大,BMI 较低,左心室质量指数较高,N 末端脑钠肽前体和肌钙蛋白 I 水平较高。

结论

在这项针对 HFpEF 的大规模前瞻性心肌组织分析中,心肌纤维化和肥大很常见,CD68+炎症增加,CA 患病率为 14%。HFpEF 中的组织分析可能通过识别相关的心肌机制来改善精准治疗。

相似文献

1
Endomyocardial Biopsy Characterization of Heart Failure With Preserved Ejection Fraction and Prevalence of Cardiac Amyloidosis.
JACC Heart Fail. 2020 Sep;8(9):712-724. doi: 10.1016/j.jchf.2020.04.007. Epub 2020 Jul 8.
2
Myocardial Gene Expression Signatures in Human Heart Failure With Preserved Ejection Fraction.
Circulation. 2021 Jan 12;143(2):120-134. doi: 10.1161/CIRCULATIONAHA.120.050498. Epub 2020 Oct 29.
3
Echocardiographic Features of Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction.
J Am Coll Cardiol. 2019 Dec 10;74(23):2858-2873. doi: 10.1016/j.jacc.2019.09.063.
4
Association between systolic ejection time and outcomes in heart failure by ejection fraction.
Eur J Heart Fail. 2020 Jul;22(7):1174-1182. doi: 10.1002/ejhf.1659. Epub 2019 Dec 21.
5
Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction.
Eur Heart J. 2015 Oct 7;36(38):2585-94. doi: 10.1093/eurheartj/ehv338. Epub 2015 Jul 28.
7
Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial.
Circ Heart Fail. 2018 Jul;11(7):e004962. doi: 10.1161/CIRCHEARTFAILURE.118.004962.
8
Growth differentiation factor 15 in heart failure with preserved vs. reduced ejection fraction.
Eur J Heart Fail. 2016 Jan;18(1):81-8. doi: 10.1002/ejhf.431. Epub 2015 Oct 25.
9
An echo score raises the suspicion of cardiac amyloidosis in Chinese with heart failure with preserved ejection fraction.
ESC Heart Fail. 2022 Dec;9(6):4280-4290. doi: 10.1002/ehf2.14164. Epub 2022 Sep 20.
10
Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction.
Circulation. 2015 Feb 10;131(6):550-9. doi: 10.1161/CIRCULATIONAHA.114.009625. Epub 2014 Dec 31.

引用本文的文献

1
Coronary microvascular disease in heart failure with preserved ejection fraction.
Physiol Rep. 2025 Aug;13(16):e70521. doi: 10.14814/phy2.70521.
2
Nanomedicine for Diagnosis and Treatment of Cardiac Fibrosis.
Int J Nanomedicine. 2025 Aug 7;20:9723-9746. doi: 10.2147/IJN.S520967. eCollection 2025.
3
T-Amylo Score for the Diagnosis of Transthyretin Cardiac Amyloidosis in Patients With Acute Heart Failure.
Int J Heart Fail. 2025 Jul 22;7(3):176-183. doi: 10.36628/ijhf.2025.0018. eCollection 2025 Jul.
4
Heart Failure Management in Cardiac Amyloidosis: Towards a Paradigm Shift.
Card Fail Rev. 2025 Jul 17;11:e15. doi: 10.15420/cfr.2024.33. eCollection 2025.
5
Circulating Immune Cell Signature Analysis in HFpEF Across Species.
Circ Res. 2025 Aug 15;137(5):682-698. doi: 10.1161/CIRCRESAHA.125.326249. Epub 2025 Jul 25.
6
Periodontitis Accelerates Progression of Heart Failure With Preserved Ejection Fraction in Mice.
JACC Basic Transl Sci. 2025 Aug;10(8):101270. doi: 10.1016/j.jacbts.2025.03.002. Epub 2025 Jun 11.
7
Decoding the Liver-Heart Axis in Cardiometabolic Diseases.
Circ Res. 2025 May 23;136(11):1335-1362. doi: 10.1161/CIRCRESAHA.125.325492. Epub 2025 May 22.
8
MO Oxygen Therapy Prevents Doxorubicin-Induced Cardiotoxicity.
Cardiol Res Pract. 2025 May 8;2025:2729462. doi: 10.1155/crp/2729462. eCollection 2025.
9
Present and future of endomyocardial biopsy in cardiac amyloidosis.
Eur Heart J Suppl. 2025 Apr 16;27(Suppl 3):iii7-iii12. doi: 10.1093/eurheartjsupp/suaf036. eCollection 2025 Mar.
10
Echocardiographic Features of Wild-Type Transthyretin Cardiac Amyloidosis From J-Case: Multicenter Survey in Japan.
JACC Asia. 2025 May;5(5):633-646. doi: 10.1016/j.jacasi.2025.01.016. Epub 2025 Mar 30.

本文引用的文献

1
A Changing Landscape of Mortality for Systemic Light Chain Amyloidosis.
JACC Heart Fail. 2019 Nov;7(11):958-966. doi: 10.1016/j.jchf.2019.07.007. Epub 2019 Oct 9.
2
Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis.
Circ Heart Fail. 2019 Sep;12(9):e006075. doi: 10.1161/CIRCHEARTFAILURE.119.006075. Epub 2019 Sep 4.
3
Screening for Transthyretin Amyloid Cardiomyopathy in Everyday Practice.
JACC Heart Fail. 2019 Aug;7(8):709-716. doi: 10.1016/j.jchf.2019.04.010. Epub 2019 Jul 10.
4
Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review.
J Am Coll Cardiol. 2019 Jun 11;73(22):2872-2891. doi: 10.1016/j.jacc.2019.04.003.
5
Natural History, Quality of Life, and Outcome in Cardiac Transthyretin Amyloidosis.
Circulation. 2019 Jul 2;140(1):16-26. doi: 10.1161/CIRCULATIONAHA.118.038169. Epub 2019 May 21.
8
A Simple, Evidence-Based Approach to Help Guide Diagnosis of Heart Failure With Preserved Ejection Fraction.
Circulation. 2018 Aug 28;138(9):861-870. doi: 10.1161/CIRCULATIONAHA.118.034646.
9
Heart Disease and Stroke Statistics-2018 Update: A Report From the American Heart Association.
Circulation. 2018 Mar 20;137(12):e67-e492. doi: 10.1161/CIR.0000000000000558. Epub 2018 Jan 31.
10
Cardiac macrophages promote diastolic dysfunction.
J Exp Med. 2018 Feb 5;215(2):423-440. doi: 10.1084/jem.20171274. Epub 2018 Jan 16.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验